TREATMENT OF ANEMIA IN GYNECOLOGICAL PATIENTS


Cite item

Full Text

Abstract

The new drug Cosmofer that is an iron(III)-hydroxide low-molecular-weight dextran complex and a chemically similar analogue of the physiological complex of ferritin with iron(III)-hydroxide has been used to treat 30 patients with iron-deficiency anemia caused by menorrhagias in the presence of endometrial hyperplasia and uterine myoma. Before treatment, hemoglobin levels in the patients ranged from 65 to 80 g/l (mean 70.1±3.5 g/l). The drug was intravenously injected dropwise in a dose of 100 mg (2 ml) every other day (thrice weekly). The course of therapy was 3 to 5 infusions; the total dose of iron administered was 300 to 500 mg. After Cosmofer treatment, the mean level of hemoglobin was as high as 98.1+2.8 g/l, which is indicative of the high clinical efficacy of the drug in the treatment of iron-deficiency and posthemorrhagic anemias in gynecological patients.

References

  1. Дедов И.И., Андреева Е.Н. Гиперплазия эндометрия: патогенез, диагностика, клиника, лечение: Метод. пособие для врачей. - М., 2001.
  2. Идельсон Л.И. Гипохромные анемии. - М.: «Медицина», 1981.
  3. Козловская Л.В., Рамеев В.В., Чеботарева Н.М. и др. Анемия хронических заболеваний // Врач. - 2006. - № 4. - С. 17-20.
  4. Манухин И.Б., Крапошина Т.П., Левченко Р.Г. Опыт лечения анемии в гинекологической практике // АГ-инфо по акуш. и гин. - 2001. - № 3. - С. 46-47.
  5. Милованова Л.Ю., Николаев А.Ю., Козлова Т.А. и др. Прогностическое значение ранней коррекции анемии у больных хронической почечной недостаточностью // Нефрол. и диализ. - 2004. - № 1. - С. 54-57.
  6. Auerbach M., Ballard H., Trout J.R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy- related anemia: a multi-centr., open-label, randomized trial// J. Clin. Oncol. - 2004. - Vol. 22. - P. 1301- 1307.
  7. Auerbach M. Intravenous iron // N. Engl. J. Med. - 2007. - Vol. 357. - P. 93-94.
  8. Balan V., Schwartz D., Wu G.Y. et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin // Am. J. Gastroenterol. - 2005. - Vol. 100. - P. 299- 307.
  9. Bellet R.E., Ghazal H, Flam M. et al. Anthonyf of the iron Sucrose Study Group. A phase III randomized, controlled study comparing iron sucrose intravenously (III) to no iron treatment of anaemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy// J.Clin. Oncol.; ASCO Annual Meeting Proceedings. Pt 1. - 2007. - Vol. 25. - abstr. 9109.
  10. Hamstra R.D., Block M.H., Schocket A.L. Intravenous iron dextran in clinical medicine// J.A.M.A. - 1980. - Vol. 243. - P. 1726-1731.
  11. Littlewood T.J., Alikhan R. The use of intravenous iron on patients with cancer-related anaemia// Br. J. Haematol. - 2008. - Vol.141, N 6. - P. 751-756.
  12. Rossert J., Munfer P. et al. Effect of early correction of anemia on the progression of chronic kidney disease// Am. J. Kidney Dis. - 2006. - Vol. 12. - P. 123- 130.
  13. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options // Am. J. Hematol. - 2004. - Vol. 76. - P. 74-78.
  14. Weiss G., Goodnough L.T. Anemia of chronic disease// N. Engl. J. Med. - 2005. - Vol. 352. - P. 1011- 1023.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies